HER2阻害剤の世界市場レポート 2024

HER2阻害剤の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.0%の年間複合成長率（CAGR）で136億1,000万米ドルに成長すると予想されます。予測される成長は、患者中心のケア、規制変更、薬剤耐性管理、世界市場の拡大、より広範な治療適応症、精密腫瘍学の導入によって推進されます。予想される動向には、患者擁護の強化、臨床調査の拡大、早期発見の改善、精密医療の利用、補助療法/術前補助療法の進歩などが含まれます。

世界中で乳がん症例の発生率が増加していることは、予測期間におけるHER-2阻害剤市場の成長に寄与する重要な要因であると予想されます。 2022年 1月の時点で、米国がん協会は、米国だけで190万人が新たにがんと診断され、609,360人ががん関連で死亡するとの予測を報告しました。乳がんは、肺がん、前立腺がん、大腸がんと並んで世界で最も一般的な4種類のがんの1つであり、合計で新規がん症例全体の43%を占めています。この乳がん発生率の上昇を考慮すると、今後数年間でHER-2阻害剤の需要が増加すると予想されます。

乳がんのケアと治療の改善を目的とした政府の取り組みにより、HER2阻害剤市場の成長を促進する態勢が整っています。これらの取り組みには、乳がんと診断された個人のアクセス、手頃な価格、およびケアの質を向上させるための政府による政策、資金提供、およびプログラムの実施が含まれます。このような政府主導の取り組みは、補助金プログラムや調査資金を通じて、乳がんの重要な治療法であるHER2阻害剤へのアクセスを改善する上で重要な役割を果たしています。一例として、世界保健機関は2021年に、乳がん死亡率を20年間で毎年 2.5%削減し、最終的に250万人の命を救うことを目標とした世界乳がんイニシアチブ（GBCI）を設立しました。乳がんのケアと治療を強化するために政府が講じた積極的な措置は、HER2阻害剤市場の成長の原動力であることを明確に示しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のHER2阻害剤市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 単独療法
• 併用療法
• 世界のHER2阻害剤市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 扁平上皮がん
• 腺がん
• 大細胞がん
• 乳がん
• その他の用途
• 世界のHER2阻害剤市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• その他のエンドユーザー

第7章 地域および国の分析

• 世界のHER2阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のHER2阻害剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• HER2阻害剤市場の競合情勢
• HER2阻害剤市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Services Inc.
  • F Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.
  • Novartis AG

第31章 その他の大手および革新的な企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly International Corp.
• Gilead Sciences Inc.
• CH Boehringer Sohn AG &Co. KG
• Applied Molecular Genetics Inc.
• Viatris Inc. US
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Catalent Inc.
• Ipsen SA
• Cipla Limited
• the Pierre Fabre Group

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

HER2 inhibitors constitute a group of medications employed in treating HER2-low and HER2-positive breast cancers across various stages, from early to metastatic. These drugs target the HER2 receptor proteins present on breast cancer cells, hindering the reception of growth signals in HER2-positive breast cancer.

Treatments mainly consist of monotherapy and combination therapy. Monotherapy involves using a single medication for treating specific conditions or diseases. These treatments find applications in various cancer types such as squamous cell carcinoma, adenocarcinoma, large cell carcinoma, as well as breast cancer, and are utilized across healthcare sectors including hospitals, clinics, and other medical settings.

The HER2 inhibitors market research report is one of a series of new reports from The Business Research Company that provides HER2 inhibitors market statistics, including HER2 inhibitors industry global market size, regional shares, competitors with a HER2 inhibitors market share, detailed HER2 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the HER2 inhibitors industry. This HER2 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The her2 inhibitors market size has grown strongly in recent years. It will grow from $8.77 billion in 2023 to $9.64 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The growth observed in the historic period can be attributed to several factors, including advancements in biotechnology, successful clinical trials, a shift in treatment approaches, substantial investments in research and development, as well as improvements in patient outcomes.

The her2 inhibitors market size is expected to see strong growth in the next few years. It will grow to $13.61 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. Forecasted growth is driven by patient-centered care, regulatory changes, drug resistance management, global market expansion, broader treatment indications, and precision oncology adoption. Anticipated trends involve increased patient advocacy, expanded clinical research, improved early detection, precision medicine utilization, and adjuvant/neoadjuvant therapy advancements.

The increasing incidence of breast cancer cases worldwide is expected to be a significant factor contributing to the growth of the HER-2 inhibitors market in the forecast period. As of January 2022, the American Cancer Society reported projections of 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the United States alone. Breast cancer ranks among the four most common types of cancer globally, alongside lung, prostate, and bowel cancer, collectively accounting for 43% of all new cancer cases. Given this rise in breast cancer incidence, there is an anticipated increase in the demand for HER-2 inhibitors in the coming years.

Government initiatives aimed at improving breast cancer care and treatment are poised to drive the growth of the HER2 inhibitors market. These initiatives involve the implementation of policies, funding, and programs by governments to enhance the accessibility, affordability, and quality of care for individuals diagnosed with breast cancer. Such government-led efforts have played a crucial role in improving access to HER2 inhibitors, a vital treatment for breast cancer, through subsidized programs and research funding. As an example, in 2021, the World Health Organization established the Global Breast Cancer Initiative (GBCI) with the goal of reducing breast cancer mortality by 2.5% annually over a 20-year period, ultimately saving 2.5 million lives. The proactive measures taken by governments to enhance breast cancer care and treatment underscore the driving force behind the growth of the HER2 inhibitors market.

The substantial costs associated with HER2 inhibitor market treatments pose a significant challenge for citizens in many countries. The imperative to control expenses and demonstrate value in healthcare is pervasive, particularly considering political uncertainty and ongoing economic strains in numerous nations that raise questions about the sustainability of public healthcare funding. This issue is particularly pronounced in less affluent countries where the absence of cost-effective cancer therapies has implications for population health, contributing to lower average life expectancies. Trastuzumab, a licensed HER2 inhibitor, stands out as one of the most expensive systemic cancer therapy procedures across various disease sites. The cost of trastuzumab in India, for example, ranged from $774.6 to $841.35 per 440 mg vial. For patients with HER2-positive early breast cancer, the treatment typically requires nearly 18 cycles of trastuzumab-based therapy, resulting in a total cost exceeding $1,335.52 in India. These exorbitant costs associated with HER2 inhibitors create financial barriers to access and are anticipated to impede the growth of the HER2 inhibitor market. The high financial burden of these treatments can limit their availability and affordability for a significant portion of the population, hindering equitable access to essential cancer therapies.

Prominent companies in the HER2 inhibitor market are strategically concentrating on the development of treatments for specific breast cancer subtypes to gain a competitive advantage. One such focus is on addressing HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer characterized by tumors that do not overexpress or produce an excess of the HER2 protein. In August 2022, AstraZeneca PLC, a leading UK-based pharmaceutical and biotechnology company, achieved a milestone as the U.S. Food and Drug Administration (FDA) granted approval for Enhertu (fam-trastuzumab deruxtecan-nxki). Enhertu is recognized as the first HER2-directed therapy designed for patients with HER2-low metastatic breast cancer. Administered through intravenous infusion, Enhertu is prescribed for adults who have undergone prior metastatic chemotherapy or experienced disease recurrence within six months of completing adjuvant chemotherapy, targeting HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

Major players in the HER2 inhibitor market are directing their efforts towards developing treatments for pre-treated HR+/HER2-metastatic breast cancer. This particular breast cancer subtype, characterized by the presence of hormone receptors (HR+), is the focus of therapeutic development. In February 2023, Gilead Sciences, Inc., a prominent US-based biopharmaceutical company, received approval from the U.S. FDA for Trodelvy (sacituzumab govitecan-hziy). Trodelvy is intended for the treatment of adults with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer. This approval is specifically granted for patients who have undergone prior endocrine-based therapies and two additional systemic treatments in the metastatic setting, addressing the needs of this particular patient population. These strategic initiatives underline the companies' commitment to developing targeted therapies for specific breast cancer subtypes, contributing to their competitive positioning in the HER2 inhibitor market.

In August 2021, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology corporation, completed the acquisition of Trillium Therapeutics Inc. for an undisclosed sum. This strategic move is intended to strengthen Pfizer's leadership position in oncology, particularly in the field of hematology. The acquisition aims to enhance Pfizer's hematology portfolio, with a focus on improving outcomes for individuals affected by blood cancers globally. Trillium Therapeutics Inc., based in Canada, is a company dedicated to developing therapies for the treatment of cancer.

Major companies operating in the her2 inhibitors market report are Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly International Corp., Gilead Sciences Inc., C.H. Boehringer Sohn AG & Co. KG, Applied Molecular Genetics Inc., Viatris Inc. US, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Catalent Inc., Ipsen SA, Cipla Limited, the Pierre Fabre Group, Biocon Biopharmaceuticals Pvt. Ltd., Innovent Biologics Inc., Halozyme Therapeutics Inc., Seattle Genetics Inc., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Mersana Therapeutics Inc., Cellestia Biotech AG

North America was the largest region in the HER2 inhibitors market in 2023. Middle East is expected to be the fastest-growing region in the HER2 inhibitors market report during the forecast period. The regions covered in the her2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the her2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The HER2 inhibitor market consists of sales of lapatinib, neratinib, tucatinib, and pyrotinib. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2 Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2 inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2 inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2 inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment: Monotherapy; Combination Therapy
• 2) By Application: Squamous Cell Carcinoma; Adenocarcinoma; Large Cell Carcinoma; Breast Cancer; Other Applications
• 3) By End User: Hospitals; Clinics; Other End Users
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. HER2 Inhibitors Market Characteristics

3. HER2 Inhibitors Market Trends And Strategies

4. HER2 Inhibitors Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global HER2 Inhibitors Market Size and Growth

• 5.1. Global HER2 Inhibitors Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global HER2 Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global HER2 Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. HER2 Inhibitors Market Segmentation

• 6.1. Global HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monotherapy
• Combination Therapy
• 6.2. Global HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Squamous Cell Carcinoma
• Adenocarcinoma
• Large Cell Carcinoma
• Breast Cancer
• Other Applications
• 6.3. Global HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Other End Users

7. HER2 Inhibitors Market Regional And Country Analysis

• 7.1. Global HER2 Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global HER2 Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific HER2 Inhibitors Market

• 8.1. Asia-Pacific HER2 Inhibitors Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China HER2 Inhibitors Market

• 9.1. China HER2 Inhibitors Market Overview
• 9.2. China HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India HER2 Inhibitors Market

• 10.1. India HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan HER2 Inhibitors Market

• 11.1. Japan HER2 Inhibitors Market Overview
• 11.2. Japan HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia HER2 Inhibitors Market

• 12.1. Australia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia HER2 Inhibitors Market

• 13.1. Indonesia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea HER2 Inhibitors Market

• 14.1. South Korea HER2 Inhibitors Market Overview
• 14.2. South Korea HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe HER2 Inhibitors Market

• 15.1. Western Europe HER2 Inhibitors Market Overview
• 15.2. Western Europe HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK HER2 Inhibitors Market

• 16.1. UK HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany HER2 Inhibitors Market

• 17.1. Germany HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France HER2 Inhibitors Market

• 18.1. France HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy HER2 Inhibitors Market

• 19.1. Italy HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain HER2 Inhibitors Market

• 20.1. Spain HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe HER2 Inhibitors Market

• 21.1. Eastern Europe HER2 Inhibitors Market Overview
• 21.2. Eastern Europe HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia HER2 Inhibitors Market

• 22.1. Russia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America HER2 Inhibitors Market

• 23.1. North America HER2 Inhibitors Market Overview
• 23.2. North America HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA HER2 Inhibitors Market

• 24.1. USA HER2 Inhibitors Market Overview
• 24.2. USA HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada HER2 Inhibitors Market

• 25.1. Canada HER2 Inhibitors Market Overview
• 25.2. Canada HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America HER2 Inhibitors Market

• 26.1. South America HER2 Inhibitors Market Overview
• 26.2. South America HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil HER2 Inhibitors Market

• 27.1. Brazil HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East HER2 Inhibitors Market

• 28.1. Middle East HER2 Inhibitors Market Overview
• 28.2. Middle East HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa HER2 Inhibitors Market

• 29.1. Africa HER2 Inhibitors Market Overview
• 29.2. Africa HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. HER2 Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. HER2 Inhibitors Market Competitive Landscape
• 30.2. HER2 Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Services Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. HER2 Inhibitors Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly International Corp.
• 31.6. Gilead Sciences Inc.
• 31.7. C.H. Boehringer Sohn AG & Co. KG
• 31.8. Applied Molecular Genetics Inc.
• 31.9. Viatris Inc. US
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Catalent Inc.
• 31.13. Ipsen SA
• 31.14. Cipla Limited
• 31.15. the Pierre Fabre Group

32. Global HER2 Inhibitors Market Competitive Benchmarking

33. Global HER2 Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The HER2 Inhibitors Market

35. HER2 Inhibitors Market Future Outlook and Potential Analysis

• 35.1 HER2 Inhibitors Market In 2028 - Countries Offering Most New Opportunities
• 35.2 HER2 Inhibitors Market In 2028 - Segments Offering Most New Opportunities
• 35.3 HER2 Inhibitors Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer